The impact of asprin use on the outcome of patients admitted to the intensive care unit with COVID-19 infection

Background: Our objective in this study is to know the impact of the use of asprin in anti-aggregation dose on the evolution during hospitalization of patients admitted in intensive care unit for a severe infection by SARS-COV-2. Methods We conducted a prospective study of patients admitted to our department with severe COVID-19 infection during the period between March 2020 and March 2022, analyzing the difference between the placebo group and the aspirin group on the primary endpoint of all-cause hospital mortality and the composite secondary endpoint of use of mechanical ventilation and thromboembolic events. Results Out of 1124 patients included, 32.6% died, with a protective effect of aspirin against placebo (Hazard-ratio = 0.691, p = 0.003), for thrombo-embolic complications, 104 events were observed, with a protective effect of aspirin (Hazard-Ratio = 0.448 and p = 0.001), finally regarding mechanical ventilation, there was no remarkable benefit on our sample. Conclusion Given the divergence of results of studies published in the literature, the availability of results of large randomized controlled trials is a necessity.